Aspirin and Enoxaparin for VTE in Trauma

• Status: Terminated
• Trial end date: 2018-05-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the addition of antiplatelet therapy (i.e. aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of venous thromboembolism (VTE) in high-risk critically injured patients. The investigators further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and enoxaparin for decreasing the incidence of VTE after trauma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Aspirin; Enoxaparin

Criteria

Inclusion Criteria:

• Age 18 years or older

• Blunt or penetrating trauma

• Requires VTE thromboprophylaxis

• High-risk for VTE

Exclusion Criteria:

• Presence of VTE upon admission

• Pregnant or nursing

• Inability to give informed consent by patient or healthcare proxy

• Contraindication to enoxaparin

• Contraindication to aspirin

• Epidural or subdural hematoma

• Presence, or removal within the last 12 hours, of an epidural or spinal catheter, or recent (within the last 12 hours) epidural or spinal anesthesia/procedures